Streptozotocin (STZ) is a glucosamine-nitrosourea compound that destroys pancreatic islet β-cells and is widely used to experimentally model type 1 diabetes mellitus (T1DM) by multiple injections of low-dose STZ.
Streptozotocin (STZ) Model Build and Efficacy Evaluation of an Anti-GCGR Antibody
Hypoglycemic effect of an anti-human GCGR antibody in STZ-induced diabetic B-hGCGR mice. (A-B) Body weight and change in blood glucose levels were measured in B-hGCGR mice (6-weeks-old) after STZ (50mg/kg) induction. (C-D) Three weeks after STZ induction, an anti-human GCGR antibody (10mg/kg, made in house) was administrated once per week. Non-fasting blood glucose and fasting blood glucose levels were measured. The anti-human GCGR antibody significantly lowered non-fasting and fasting blood glucose levels in STZ-induced diabetic B-hGCGR mice. Values are expressed as mean ± SEM. *p<0.05, **p<0.01,***p<0.001.